The tweet was deleted by the author.
But we saved everything 🙂.
Upstream Bio, Inc. released its financial results for the fourth quarter and full year 2025.
The company also detailed its Phase 3 development strategy for its lead asset, verekitug. The new strategy signals a critical step in Upstream Bio, Inc.'s clinical pipeline progression. Full financial details and development timelines were made available in the company's latest statement. Further updates on program milestones are anticipated as the clinical development plan advances.
Upstream Bio, Inc. recently participated in major healthcare conferences, with CEO Rand Sutherland engaging in fireside chats in March at key industry events, according to a company announcement here. Sutherland also led a live discussion at the TD Cowen Healthcare Conference, which was made available for replay here. These public engagements came as the company advanced its clinical and corporate communications strategy.